Loading organizations...
§ Private Equity · New York City, NY, USA
Private equity firm focused on healthcare. Acquires, builds, and grows companies in medical products, services, tech.
Altaris Capital Partners is a healthcare-focused private equity firm based in New York City that specializes in growth-oriented buyouts and complex corporate carve-outs. The firm invests exclusively across the broader healthcare industry, targeting established companies involved in pharmaceuticals, medical devices, diagnostics, and healthcare information technology. Operating with a dedicated team of 35 staff members, the organization currently manages over $9 billion in equity capital and has invested in more than 50 companies since its inception. Its active investment portfolio features notable healthcare enterprises including Sharecare, which it agreed to acquire for $518 million, as well as Padagis and HealthTronics. In 2021, the investment firm successfully closed its fifth flagship fund with $3.2 billion in capital commitments to further support its acquisition strategy. Altaris Capital Partners was founded in 2003 by George Aitken-Davies and Daniel Tully.
Key people at Altaris Capital Partners.
Key people at Altaris Capital Partners.
Altaris Capital Partners is a New York-based private equity investment firm founded in 2002/2003 that exclusively focuses on the healthcare industry. Its mission is to acquire and build companies that deliver innovation, efficiency, and value to the healthcare system while generating attractive financial returns for investors. Altaris invests across various healthcare subsectors including life sciences/pharmaceuticals, provider services, and non-reimbursement healthcare industries. The firm targets both control and minority equity investments, typically engaging in growth-oriented buyouts and complex, value-based situations. Its portfolio includes companies like CMP Pharma (specialty pharmaceuticals), HealthTronics (medical devices and services), Paramit (medical device manufacturing), and Quantum Health (consumer healthcare programs for employers), reflecting a broad impact on healthcare innovation and service delivery[1][3][4][7].
Founded in 2002/2003, Altaris was established by partners with deep healthcare industry expertise, evolving its focus to leverage specialized knowledge and networks to identify undervalued or overlooked investment opportunities. The firm has invested in over 50 companies to date, with a track record of 28 realized or substantially realized investments, managing approximately $2.5 billion in equity capital. Altaris emphasizes active engagement with portfolio companies to improve patient outcomes, reduce unnecessary healthcare costs, increase operational efficiency, and align stakeholder incentives. Its investment approach often involves carve-outs, corporate partnerships, and providing first institutional capital to founder- or family-owned businesses[1][4][6].
Altaris rides the ongoing trend of healthcare system transformation driven by payment model reforms, clinician shortages, value-based purchasing, and increased consumer engagement. The timing is critical as healthcare faces pressure to improve outcomes while controlling costs, creating demand for innovative solutions and efficient service delivery. Altaris influences the ecosystem by providing capital and strategic support to companies that address these systemic challenges, fostering innovation in pharmaceuticals, medical devices, and healthcare services. Its investments help accelerate the adoption of technologies and business models that improve healthcare efficiency and patient care[4].
Looking ahead, Altaris is positioned to continue capitalizing on the healthcare sector’s complexity and growth potential, especially as value-based care and digital health solutions gain prominence. The firm’s deep sector knowledge and active investment approach suggest it will remain influential in shaping healthcare innovation and operational improvements. Trends such as personalized medicine, healthcare consumerism, and regulatory changes will likely shape its investment focus and portfolio evolution. Altaris’s ability to identify and scale companies that deliver measurable healthcare value will be central to its future success and impact on the healthcare ecosystem[3][4][6].